More than half of males with X-linked adrenoleukodystrophy (ALD) develop progressive, inflammatory cerebral demyelination (cerebral adrenoleukodystrophy). Treatment for cerebral adrenoleukodystrophy is limited with no standard therapies for advanced cerebral adrenoleukodystrophy. We reviewed cerebral adrenoleukodystrophy literature and expert opinion, compiling immunopathology, biomarkers, and therapies tested.
Methods
We reviewed published literature from January 1, 1970, through November 1, 2024, and surveyed expert clinicians worldwide caring for cerebral adrenoleukodystrophy patients for unpublished agent use.
Results
We identified 20 publications with primary data on human cerebral adrenoleukodystrophy immunopathology. Seventeen publications reported cerebral adrenoleukodystrophy biomarkers. We identified 14 publications reporting use of 7 different agents; unpublished clinician reports identified use of 9 different agents.
Conclusions
Cerebral adrenoleukodystrophy immunopathology represents complex dysregulation of cytokines, macrophages, T cells, astrocytes, oligodendrocytes, and microglia. Partial responses to cerebral adrenoleukodystrophy were noted with intravenous immunoglobulin, sirolimus, leriglitazone, and mycophenolate. Our findings suggest consideration for a randomized platform trial of immunomodulatory agents for advanced cerebral adrenoleukodystrophy.
BernheimerHBudkaHMüllerP. Brain tissue immunoglobulins in adrenoleukodystrophy: a comparison with multiple sclerosis and systemic lupus erythematosus. Acta Neuropathol. 1983;59(2):95–102. doi:https://doi.org/10.1007/bf00691593
5.
GriffinDEMoserHWMendozaQMoenchTRO’TooleSMoserAB. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol. 1985;18(6):660–664. doi:https://doi.org/10.1002/ana.410180606
6.
PowersJMLiuYMoserABMoserHW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992;51(6):630–643. doi:https://doi.org/10.1097/00005072-199211000-00007
KatsuragiTIsekiEKosakaK, et al.Immunohistochemical investigation of human leukocyte antigen (HLA)-DR-positive astrocytes in adrenoleukodystrophy brain. Neurosci Lett. 1996;219(3):207–210. doi:https://doi.org/10.1016/s0304-3940(96)13215-8
9.
McGuinnessMCPowersJMBiasWB, et al.Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol. 1997;75(1-2):174–182. doi:https://doi.org/10.1016/s0165-5728(97)00020-9
10.
ItoMBlumbergBMMockDJ, et al.Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol. 2001;60(10):1004–1019. doi:https://doi.org/10.1093/jnen/60.10.1004
11.
PaintliaASGilgAGKhanMSinghAKBarbosaESinghI. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis. 2003;14(3):425–439. doi:https://doi.org/10.1016/j.nbd.2003.08.013
12.
PicardFGuidouxSMartinTAubourgPPasqualiJ. T-cell receptor Vβ gene usage in CSF lymphocytes in X-linked adrenoleukodystrophy. J Mol Recognit. 2005;18(3):254–261. doi:https://doi.org/10.1002/jmr.727
13.
GörtzALPeferoenLANGerritsenWHNoortJvBugianiMAmorS. Heat shock protein expression in cerebral X-linked adrenoleukodystrophy reveals astrocyte stress prior to myelin loss. Neuropathol Appl Neurobiol. 2018;44(4):363–376. doi:https://doi.org/10.1111/nan.12399
14.
EichlerFSRenJCossoyM, et al.Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?Ann Neurol. 2008;63(6):729–742. doi:https://doi.org/10.1002/ana.21391
15.
GautronASGiquelBBeaudoinL, et al.Invariant NKT cells in adrenoleukodystrophy patients and mice. J Neuroimmunol. 2010;229(1-2):204–211. doi:https://doi.org/10.1016/j.jneuroim.2010.09.003
16.
LaunayNRuizMGrauL, et al.Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. Acta Neuropathol. 2017;133(2):283–301. doi:https://doi.org/10.1007/s00401-016-1655-9
17.
BergnerCGMeerFvdWinklerA, et al.Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy. Glia. 2019;67(6):1196–1209. doi:https://doi.org/10.1002/glia.23598
18.
BergnerCGGencNHametnerS, et al.Concurrent axon and myelin destruction differentiates X-linked adrenoleukodystrophy from multiple sclerosis. Glia. 2021;69(10):2362–2377. doi:https://doi.org/10.1002/glia.24042
19.
VoornJvdPouwelsPJWPowersJM, et al.Correlating quantitative MR imaging with histopathology in X-linked adrenoleukodystrophy. Am J Neuroradiol. 2011;32(3):481–489. doi:https://doi.org/10.3174/ajnr.a2327
20.
PoissonLMKaurNFelicellaMMSinghJ. System-based integrated metabolomics and microRNA analysis identifies potential molecular alterations in human X-linked cerebral adrenoleukodystrophy brain. Hum Mol Genet. 2023;32(23):3249–3262. doi:https://doi.org/10.1093/hmg/ddad144
21.
FeigenbaumVGélotACasanovaPDaumas-DuportCAubourgPDubois-DalcqM. Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients. Neurobiol Dis. 2000;7(6):600–612. doi:https://doi.org/10.1006/nbdi.2000.0315
22.
MayatepekEBaumannMMeissnerTHanefeldFKorenkeGC. Role of leukotrienes as indicators of the inflammatory demyelinating reaction in X-linked cerebral adrenoleukodystrophy. J Neurol. 2003;250(10):1259–1260. doi:https://doi.org/10.1007/s00415-003-0189-y
23.
WeinhoferIRommerPZierfussB, et al.Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. Nat Commun. 2021;12(1):1816. doi:https://doi.org/10.1038/s41467-021-22114-2
24.
WangHDavisonMDKramerML, et al.Evaluation of neurofilament light chain as a biomarker of neurodegeneration in X-linked childhood cerebral adrenoleukodystrophy. Cells. 2022;11(5):913. doi:https://doi.org/10.3390/cells11050913
25.
WeinhoferIRommerPGleissA, et al.Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy. eBioMedicine. 2023;96:104781. doi:https://doi.org/10.1016/j.ebiom.2023.104781
26.
MoserHLoesDMelhemE, et al.X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. a study involving 372 patients. Neuropediatrics.2000;31(5):227–239. doi:https://doi.org/10.1055/s-2000-9236
27.
MelhemERLoesDJGeorgiadesCSRaymondGVMoserHW. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol. 2000;21(5):839–844.
MillerWPMantovaniLFMuzicJ, et al.Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy: a biomarker for inflammation and predictor of outcome following transplantation in higher risk patients. Am J Neuroradiol. 2016;37(2):367–372. doi:https://doi.org/10.3174/ajnr.a4500
30.
LundTCNgMOrchardPJ, et al.Volume of gadolinium enhancement and successful repair of the blood-brain barrier in cerebral adrenoleukodystrophy. Biol Blood Marrow Transplant. 2020;26(10):1894–1899. doi:https://doi.org/10.1016/j.bbmt.2020.06.019
31.
ShahNSinghI. MicroRNA profiling identifies miR-196a as differentially expressed in childhood adrenoleukodystrophy and adult adrenomyeloneuropathy. Mol Neurobiol. 2017;54(2):1392–1403. doi:https://doi.org/10.1007/s12035-016-9746-0
32.
PetrilloSPiemonteFPastoreA, et al.Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Mol Genet Metab. 2013;109(4):366–370. doi:https://doi.org/10.1016/j.ymgme.2013.05.009
33.
TurkBRTheisenBENemethCL, et al.Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. JAMA Neurol. 2017;74(5):519. doi:https://doi.org/10.1001/jamaneurol.2016.5715
34.
OrchardPJNasceneDRGuptaA, et al.Cerebral adrenoleukodystrophy is associated with loss of tolerance to profilin. Eur J Immunol. 2019;49(6):947–953. doi:https://doi.org/10.1002/eji.201848043
35.
HarenKvWilkesJMoserAB, et al.Vitamin D status and latitude predict brain lesions in adrenoleukodystrophy. Ann Child Neurol Soc. 2023;1(2):155–161. doi:https://doi.org/10.1002/cns3.4
36.
JaspersYRJYskaHAFBergnerCG, et al.Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy. Commun Med. 2024;4(1):175. doi:https://doi.org/10.1038/s43856-024-00605-9
37.
OrchardPJLundTMillerW, et al.Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. J Neuroinflammation. 2011;8(1):144. doi:https://doi.org/10.1186/1742-2094-8-144
38.
LundTCStademPSPanoskaltsis-MortariA, et al.Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity. PLoS One. 2012;7(2):e32218. doi:https://doi.org/10.1371/journal.pone.0032218
39.
HashemiESrivastavaINAguirreA, et al.A novel mouse model for cerebral inflammatory demyelination in X-linked adrenoleukodystrophy: insights into pathogenesis and potential therapeutic targets. Ann Neurol. 2025;97(2):296-312. doi:https://doi.org/10.1002/ana.27117
40.
KakumotoTMatsukawaTIshiuraHMoriHTsujiSTodaT. Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy. Ann Clin Transl Neurol. 2023;10(7):1230–1238. doi:https://doi.org/10.1002/acn3.51818
41.
TaghizadehLAKingCJNasceneDR, et al.Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy. Sci Rep. 2022;12(1):7985. doi:https://doi.org/10.1038/s41598-022-11552-7
42.
SignoriniCFeliceCDDurandT, et al.Isoprostanoid plasma levels are relevant to cerebral adrenoleukodystrophy disease. Life. 2022;12(2):146. doi:https://doi.org/10.3390/life12020146
43.
CappaMBertiniEBalzoPdCambiasoPBiaseADSalvatiS. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol, Neurosurg Psychiatry. 1994;57(suppl):69. doi:https://doi.org/10.1136/jnnp.57.suppl.69
44.
MuraiHSasagasakoNYoshimuraTKiraJGotoI. Gadolinium-MRI findings of two adrenoleukodystrophy cases treated with gamma-globulin. Rinsho Shinkeigaku Clin Neurol. 1992;32(4):416–420.
45.
MiikeTTakuKTamuraT, et al.Clinical improvement of adrenoleukodystrophy following intravenous gammaglobulin therapy. Brain Dev. 1989;11(2):134–137. doi:https://doi.org/10.1016/s0387-7604(89)80083-x
OkaASaitoMKubotaMSakakiharaYYanagisawaM. Temporary improvement of neurological symptoms with gammaglobulin therapy in a boy with adrenoleukodystrophy. Brain Dev. 1996;18(2):119–121. doi:https://doi.org/10.1016/0387-7604(95)00106-9
48.
SinghapakdiKSharmaKMaertensP. Fulminating autoimmune demyelination with optic neuropathy in a case of pediatric cerebral adrenoleukodystrophy: case report and review of the literature. J Pediatr Neurol. 2021;19(06):377–383. doi:https://doi.org/10.1055/s-0041-1727143
49.
LuoXMLiuLYWangQH, et al.Exploratory study of autophagy inducer sirolimus for childhood cerebral adrenoleukodystrophy. Front Pediatr. 2023;11:1187078. doi:https://doi.org/10.3389/fped.2023.1187078
50.
GolseMWeinhoferIBlancoB, et al.Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. 2024;147(10):3344–3351. doi:https://doi.org/10.1093/brain/awae169
51.
RosewichHNesslerSBrückWGärtnerJ. B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy. Ther Adv Neurol Disord. 2019;12:1756286419868133. doi:https://doi.org/10.1177/1756286419868133
52.
HorvathGEichlerFPoskittKStockler-IpsirogluS. Failure of repeated cyclophosphamide pulse therapy in childhood cerebral X-linked adrenoleukodystrophy. Neuropediatrics. 2012;43(1):048–052. doi:https://doi.org/10.1055/s-0032-1307455
53.
NaiduSBresnanMJGriffinDO’TooleSMoserHW. Childhood adrenoleukodystrophy: failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol. 1988;45(8):846–848. doi:https://doi.org/10.1001/archneur.1988.00520320032011
54.
StumpfDAHaywardAHaasRFrostMSchaumburgHH. Adrenoleukodystrophy: failure of immunosuppression to prevent neurological progression. Arch Neurol. 1981;38(1):48–49. doi:https://doi.org/10.1001/archneur.1981.00510010074014
55.
KorenkeGCChristenHJKruseBHunnemanDHHanefeldF. Progression of X-linked adrenoleukodystrophy under interferon-β therapy. J Inherit Metab Dis. 1997;20(1):59–66. doi:https://doi.org/10.1023/a:1005361607523
56.
ZierfussBWeinhoferIKühlJ, et al.Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. Ann Clin Transl Neurol. 2020;7(5):639–652. doi:https://doi.org/10.1002/acn3.51015
Ranea-RoblesPLaunayNRuizM, et al.Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. EMBO Mol Med. 2018;10(8):e8604. doi:https://doi.org/10.15252/emmm.201708604
62.
ZhangQLinJYangMLiZZhangMBuB. Therapeutic potential of natural killer cells in neuroimmunological diseases. Biomed Pharmacother. 2024;173:116371. doi:https://doi.org/10.1016/j.biopha.2024.116371
63.
YulyaningsihESuhJHFanokM, et al.DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response. eLife. 2024;12:RP92173. doi:https://doi.org/10.7554/elife.92173
GreenAJGelfandJMCreeBA, et al.Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481–2489. doi:https://doi.org/10.1016/s0140-6736(17)32346-2
66.
RatchfordJNEndresCJHammoudDA, et al.Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259(6):1199–1205. doi:https://doi.org/10.1007/s00415-011-6337-x
67.
CreeBACBennettJLKimHJ, et al.Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. doi:https://doi.org/10.1016/s0140-6736(19)31817-3
68.
ScheibeFOstendorfLPrüssH, et al.Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847–1854. doi:https://doi.org/10.1111/ene.15266
69.
MontalbanXVermerschPArnoldDL, et al.Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119–1132. doi:https://doi.org/10.1016/s1474-4422(24)00328-4
70.
LiuYFanQJiaCWanQYangH. Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: a case series. Medicine (Baltimore).2023;102(25):e34079. doi:https://doi.org/10.1097/md.0000000000034079
RemlingerJMadaraszAGuseK, et al.Antineonatal fc receptor antibody treatment ameliorates MOG-IgG–associated experimental autoimmune encephalomyelitis. Neurol Neuroimmunol Neuroinflammation. 2022;9(2):e1134. doi:https://doi.org/10.1212/nxi.0000000000001134
73.
KleiterITraboulseeAPalaceJ, et al.Long-term efficacy of satralizumab in AQP4-IgG–seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflammation. 2022;10(1):e200071. doi:https://doi.org/10.1212/nxi.0000000000200071
74.
FritzDTimmermansWMCvan LaarJAM, et al.Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflammation. 2020;7(5):e847. doi:https://doi.org/10.1212/nxi.0000000000000847
75.
ArcanAKızılkılıçEKGündüzAUnkunRVezzaniAÖzkaraÇ. Rasmussen’s syndrome treated with anakinra. J Neurol. 2024;271(2):723–726. doi:https://doi.org/10.1007/s00415-023-12072-8
76.
DangCLuYChenXLiQ. Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the Janus kinase/signal transducer and activator of transcription signaling pathway. Front Immunol. 2021;12:650708. doi:https://doi.org/10.3389/fimmu.2021.650708
77.
PittockSJFujiharaKPalaceJ, et al.Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler J. 2021;28(3):480–486. doi:https://doi.org/10.1177/13524585211038291
The Multiple Sclerosis Study Group, Wolinsky. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990;27(6):591–605. doi:https://doi.org/10.1002/ana.410270603
80.
de StefanoNBarkhofFMontalbanX, et al.Early reduction of MRI activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflammation. 2022;9(4):e1187. doi:https://doi.org/10.1212/nxi.0000000000001187
RidleyBNoninoFBaldinECasettaIIulianoGFilippiniG. Azathioprine for people with multiple sclerosis. Cochrane Database Syst Rev. 2024;2024(12):CD015005. doi:https://doi.org/10.1002/14651858.cd015005.pub2
83.
BravoGÁCedeñoRRCasadevallMPRamió-TorrentàL. Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives. Cells. 2022;11(13):2058. doi:https://doi.org/10.3390/cells11132058
84.
MorrowSACliftFDevonshireV, et al.Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord. 2022;65:103995. doi:https://doi.org/10.1016/j.msard.2022.103995
85.
BayryJMisraNLatryV, et al.Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10(3):165–169. doi:https://doi.org/10.1016/s1246-7820(03)00035-1
86.
ReevesHMWintersJL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–351. doi:https://doi.org/10.1111/bjh.12629
YadavSKItoNSoinDItoKDhib-JalbutS. Dimethyl fumarate suppresses demyelination and axonal loss through reduction in pro-inflammatory macrophage-induced reactive astrocytes and complement C3 deposition. J Clin Med. 2021;10(4):857. doi:https://doi.org/10.3390/jcm10040857
89.
PaganiFTestiCGrimaldiA, et al.Dimethyl fumarate reduces microglia functional response to tissue damage and favors brain iron homeostasis. Neuroscience. 2020;439:241–254. doi:https://doi.org/10.1016/j.neuroscience.2019.10.041
90.
KunchokAAksamitAJDavisJM, et al.Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937–946. doi:https://doi.org/10.1001/jamaneurol.2020.1162
91.
KangYRKimKHHyunJWKimSHKimHJ. Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: a case series. Mult Scler Relat Disord. 2024;91:105859. doi:https://doi.org/10.1016/j.msard.2024.105859
92.
RhenTCidlowskiJA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723. doi:https://doi.org/10.1056/nejmra050541
93.
LauerADaXHansenMB, et al.ABCD1 dysfunction alters white matter microvascular perfusion. Brain. 2017;140(12):3139–3152. doi:https://doi.org/10.1093/brain/awx262
94.
LauerASperoniSLChoiM, et al.Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nat Commun. 2023;14(1):1900. doi:https://doi.org/10.1038/s41467-023-37262-w
95.
ZhouXMaCYZhangX, et al.Development of a rabbit model for adrenoleukodystrophy: a pilot study on gene therapy using rAAV9. Mol Ther Nucleic Acids. 2025;36(1):102469. doi:https://doi.org/10.1016/j.omtn.2025.102469
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
